A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France
← catalyst calendarNCT04550247 · readout in 208 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
362actual
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-02 | actual | When the study began enrolling |
| Primary completion | 2027-03-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-15 | estimated | The whole study's end, after follow-up |
| First posted | 2020-09-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2022-03-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Melanoma
Primary outcome
what the primary-completion date above is the date OFRelapse-Free Survival (RFS)
measured up to 60 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed